MARKET MOVES

JM Financial calls Metropolis Healthcare ‘best-value diagnostic stock’, sees up to 27% upside

2026-08-28·Economic Times·Impact 1/5 · Low

MeridStreet AI summary

JM Financial has upgraded its assessment of Metropolis Healthcare, calling it the best-value diagnostic stock in India. This upgrade is based on the company's attractive valuations, expansion of its network, and improving margins. As a result, Metropolis Healthcare now has a Buy rating from JM Financial, with a target price of Rs 734, which implies a potential upside of up to 27% for investors. This positive assessment could boost investor confidence in the stock.

Source reporting

Read the source report: Economic Times →

MeridStreet analysis

Why it matters

JM Financial has retained its Buy rating on Metropolis Healthcare, indicating a potential upside of 27. 2%.

Market impact

Impact score

1 / 5

Market signal

Positive / risk-on

Markets & countries in focus

India

Transmission channels

Buy rating retained→Target price set→Investor interest rises→Stock price increases→Market confidence boosts

Likely winners & losers

Winners

Metropolis Healthcare
Diagnostic stocks

Related coverage

What is emotional regulation? A child psychologist explains The Conversation · 2026-08-06

Explore the intelligence

Live news feed

Real-time global markets, trade & geopolitics

All stories

Every tracked story cluster

Global macro

GDP, inflation & policy rates across major economies

Open the live MeridStreet terminal →

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Economic Times. For information only — not financial advice.